KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation and Depletion: 2011-2015

Historic Depreciation and Depletion for Supernus Pharmaceuticals (SUPN) over the last 4 years, with Jun 2015 value amounting to $160,000.

  • Supernus Pharmaceuticals' Depreciation and Depletion fell 9.09% to $160,000 in Q2 2015 from the same period last year, while for Jun 2015 it was $670,000, marking a year-over-year increase of 3.88%. This contributed to the annual value of $699,000 for FY2014, which is 36.52% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $160,000 for Q2 2015, which was up 2.56% from $156,000 recorded in Q1 2015.
  • Supernus Pharmaceuticals' 5-year Depreciation and Depletion high stood at $156.0 million for Q2 2012, and its period low was $105,000 during Q2 2013.
  • In the last 3 years, Supernus Pharmaceuticals' Depreciation and Depletion had a median value of $158,500 in 2013 and averaged $152,600.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Depreciation and Depletion spiked by 103,211.26% in 2012, and later plummeted by 99.93% in 2013.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Depreciation and Depletion stood at $171,000 in 2011, then declined by 4.09% to $164,000 in 2012, then decreased by 4.27% to $157,000 in 2013, then increased by 8.28% to $170,000 in 2014, then declined by 9.09% to $160,000 in 2015.
  • Its last three reported values are $160,000 in Q2 2015, $156,000 for Q1 2015, and $170,000 during Q4 2014.